CA 19-9 ELISA
Specification:
Catalog Number: CA 19-9 HU-LB018
Description: Cancer Antigen 19-9 ELISA
Sample Type: Serum
Sample Size: 10 µl
Available Sizes: 96 Wells
Range: 0-600 U/ml
Sensitivity: 10.0 U/ml
Incubation: 3 hour(s) 20 minutes (s)
Protocol: Cancer Antigen 19-9 ELISA
Regulatory Status: RUO
Product Distribution: Available worldwide
CA 19-9 ELISA - For the quantitative determination of Cancer Antigen (CA)19-9 concentration in human Serum.
A group of mucin type glycoprotein Sialosyl Lewis Antigens (SLA), such as CA19-9 and CA19-5, have
come to be recognized as circulating cancer associated antigens for gastrointestinal cancer. CA19-9
represents the most important and basic carbohydrate tumor marker. The immunohistologic distribution of
CA19-9 in tissues is consistent with the quantitative determination of higher CA19-9 concentrations in
cancer than in normal or inflamed tissues. Recently reports indicates that the serum CA19-9 level is
frequently elevated in the serum of subjects with various gastrointestinal malignancies, such as pancreatic,
colorectal, gastric and hepatic carcinomas. Together with CEA, elevated CA19-9 is suggestive of
gallbladder neoplasm in the setting of inflammatory gallbladder disease. This tumor-associated antigen
may also be elevated in some non-malignant conditions. Research studies demonstrate that serum CA
19-9 values may have utility in monitoring subjects with the above-mentioned diagnosed malignancies. It
has been shown that a persistent elevation in serum CA19-9 value following treatment may be indicative of
occult metastatic and/or residual disease. A persistently rising serum CA 19-9 value may be associated
with progressive malignant disease and poor therapeutic response. A declining CA 19-9 value may be
indicative of a favorable prognosis and good response to treatment.